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Background: Acetate metabolism in skeletal muscle is regulated by acetylCoA synthetase (ACS). The main
function of ACS is to provide cells with acetylCoA, a keymolecule for numerous metabolic pathways including
fatty acid and cholesterol synthesis and the Krebs cycle.
Methods: Hyperpolarized [1-13C]acetate prepared via dissolution dynamic nuclear polarization was injected
intravenously at different concentrations into rats. The 13C magnetic resonance signals of [1-13C]acetate
and [1-13C]acetylcarnitine were recorded in vivo for 1 min. The kinetic rate constants related to the transfor-
mation of acetate into acetylcarnitine were deduced from the 3 s time resolution measurements using two
approaches, either mathematical modeling or relative metabolite ratios.
Results: Although separated by two biochemical transformations, a kinetic analysis of the 13C label ﬂow from
[1-13C]acetate to [1-13C]acetylcarnitine led to a unique determination of the activity of ACS. The in vivoMichaelis
constants for ACS were KM = 0.35 ± 0.13 mM and Vmax = 0.199 ± 0.031 μmol/g/min.
Conclusions: The conversion rates from hyperpolarized acetate into acetylcarnitine were quantiﬁed in vivo and,
although separated by two enzymatic reactions, these rates uniquely deﬁned the activity of ACS. The conversion
rates associatedwith ACS were obtained using two analytical approaches, both methods yielding similar results.
General signiﬁcance: This study demonstrates the feasibility of directly measuring ACS activity in vivo and, since
the activity of ACS can be affected by various pathological states such as cancer or diabetes, the proposedmethod
could be used to non-invasively probe metabolic signatures of ACS in diseased tissue.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Acetate plays an important role in human and rodent energy
metabolism and it is readily taken up by skeletal muscle [1–3] (see
Fig. 1). Acetate is a pyruvate dehydrogenase (PDH) independent
acetylator of tissue carnitine and free coenzyme A (CoA) [1] and is
converted into acetylCoA via a reaction catalyzed by the enzyme
acetylCoA synthetase (ACS). The main function of ACS is to provide
the cell with acetylCoA, a key molecule for numerous metabolic
pathways including fatty acid and cholesterol synthesis and the
tricarboxylic acid (TCA) cycle. ACS has been previously shown to
be the rate limiting enzyme in the metabolism of acetate [4,5].oA, acetyl coenzyme A; ACS,
, acetate; A.Car, acetylcarnitine
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rights reserved.Pathological and substrate changes have an effect on the activity of
ACS, which has been reported to be turned off faster than other CoA
dependent enzymes during free CoA decrease. [6]. Its activity in-
creases together with insulin in response to a carbohydrate-rich diet
to induce fatty acid synthesis [7].
Carnitine acetyltransferase (CAT) converts acetylCoA to
acetylcarnitine, a reaction which has a well maintained equilibrium [8].
In skeletal muscle, carnitine plays two metabolic roles: on one hand it
serves as a shuttle of acetyl groups and long chain fatty acids from the
cytosol into mitochondria and thus enabling beta oxidation [9–13]. On
the other hand it can act as a buffer for excess acetylCoA when the
rate of acetylCoA generation is greater than its entry into the TCA
cycle. The general function of CAT is to balance rapid changes in the
acetylCoA/CoA ratio in both the cytoplasmic and mitochondrial com-
partments [11]. In rat skeletal muscle, 98% to 99% of extra acetylCoA
produced is buffered by acetylcarnitine [14]. Since the mitochondrial
innermembrane is impermeable to acetylCoA, CAT is essential in theme-
tabolism of acetate, as was shown in canine skeletal muscle [15]. After
acetate
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Fig. 1. Schematic representation of the uptake andmetabolism of acetate in rat skeletal muscle in vivo. Acetate diffusion into the muscle cell is facilitated by a concentration gradient.
Via acetylCoA synthetase (ACS), it is transformed to acetylCoA. Carnitine acetyltransferase (CAT) reversibly converts acetylCoA to acetylcarnitine from which there is a ﬂux into the
mitochondria (Vout).
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membrane via acetylcarnitine translocase (ATL) where a mitochondrial
CAT transfers the acetyl group back to CoASH upon which acetylCoA
can enter the TCA cycle.
Acetate, being a short chain fatty acid has a typical plasma concen-
tration of 0.2 mM in rats which decreases during fasting and increases
in a diabetic state [5]. Its oxidation has been deemed signiﬁcant since
it is rapidly cleared from the blood if injected in vivo or generated
fromprecursors such as ethanol in the liver [16]. Acetate uptake by rest-
ing skeletal muscle is driven by a concentration gradient and is propor-
tional to the plasma concentration [17,18]. In a single passage of blood,
half of the acetate presented to the tissue was removed by the muscle
tissue indicating a high afﬁnity for acetate [5]. In contracting skeletal
muscle however, acetate oxidation decreased, indicating a shift of sub-
strate preference compared to resting skeletal muscle [19].
To date, most of the information concerning these enzyme activi-
ties in rat has however been collected from cell cultures and tissue
preparations [5,20]. The ability to measure ACS and CAT activities
in vivo is expected to provide valuable insight in normal and patho-
logical conditions.
13C magnetic resonance spectroscopy (MRS) is a well-established
technique to investigate in vivometabolic processes [21] and it can be
coupled with standard MR imaging techniques that gives anatomical
information. The advent of dissolution dynamic nuclear polarization
(DNP) allows for the measurement of speciﬁc metabolic reactions in
real-time, thanks to a sensitivity enhancement of several orders of
magnitude [22,23], which is now being used in human trials in the
investigation of prostate cancer [24].
The incorporation of 13C into acetylcarnitine has been reported
after the infusion of hyperpolarized 13C acetate [25] and after the in-
jection of [2-13C]pyruvate [26,27]. The aim of the present study was
to elucidate the enzyme kinetics involved in the in vivo transforma-
tion of acetate to acetylcarnitine in rat skeletal muscle, by extracting
quantitative kinetic rate constants from the observed [1-13C]
acetylcarnitine labeling dynamics following the infusion of different
substrate concentrations of hyperpolarized [1-13C]acetate.
2. Material and methods
All chemicalswere purchased from Sigma-Aldrich, Basel, Switzerland.
[1-13C]sodium acetate was dissolved in a concentration ranging from
1.0 to 4.5 M in a 1:2 mixture of d6-EtOD/D2O containing 33 mM of
TEMPO (2,2,6,6-Tetramethyl-1-piperidinyloxy) free radical. 300 μL
of the resulting solution was rapidly frozen in liquid nitrogen to form
10 μL beads that were placed in a 5 T custom-designed DNP polarizer
[28,29]. The 13C nuclear spins were dynamically polarized at 1.02 ±
0.03 K for 2 h using 30 mW of microwave power at 140.18 GHz. The
sample was consecutively rapidly dissolved using 6.0 mL of super-
heated D2O and transferred within 2 s to a separator/infusion pumplocated inside a 9.4 T horizontal bore magnet containing 0.6 mL of
phosphate buffered saline and heparin. Subsequently, 1.0 mL of the
room-temperature hyperpolarized acetate solution was automatically
infused into the animal within 5 s. From in vitro measurements per-
formed inside the separator/infusion pump, it was determined that
the 13C polarization at the time of injection was 13 ± 2% [30]. No phys-
iological changes were observed during the injection.
All animal experiments were conducted according to federal ethi-
cal guidelines and were approved by the local regulatory body. Male
Sprague Dawley® rats (275–325 g) were anesthetized with 1.5%
isoﬂurane in oxygen (n = 19). A catheter was placed into the femoral
vein for intravenous delivery of the hyperpolarized acetate solution.
The respiration rate and temperature were monitored and maintained
during the experiment.
All experiments were performed with a Direct Drive spectrometer
(Agilent, Palo Alto, CA, USA) interfaced to an actively shielded 9.4 T
magnet with a 31 cm horizontal bore (Magnex Scientiﬁc, Abingdon,
UK). A home-built 1H/13C probe consisting of a pair of 10 mm diam-
eter 1H surface coils in quadrature mode and a 10 mm diameter 13C
surface coil was placed over the hind leg of the rat to selectively ex-
cite and detect skeletal muscle tissue, more speciﬁcally, the gastroc-
nemius muscles. A hollow glass sphere with a 3 mm inner diameter
(Wilmad-LabGlass, NJ, USA) was ﬁlled with a 1 M [1-13C]glucose
solution and used to adjust the pulse power and set the reference
frequency. Once the animal was positioned inside the magnet, ten
axial 1 mm thick slices were acquired using a gradient echo sequence
(TR = 50 ms, TE = 3 ms, ﬁeld of view = 30 × 30 mm2, matrix =
128 × 128, ﬂip angle = 30°) from which the volume of interest was
selected. The static magnetic ﬁeld was homogenized in a 600 μL
(6 × 10 × 10 mm3) voxel to reduce the localized proton line width
to 20 Hz using the FASTESTMAP shimming protocol [31]. Series
of single-pulse 13C acquisitions were sequentially recorded starting
12 s after dissolution using 30° adiabatic RF pulses (BIR4) applied
every 3 s with 1H decoupling during acquisition (WALTZ). The adia-
batic pulse offset and power was set such as to ensure a homoge-
neous 30° excitation of substrate and metabolite resonances in the
entire volume of interest. At the end of each in vivo experiment,
200 μL of the residual solution was collected from the infusion
pump and the [1-13C]acetate concentration was measured in a high-
resolution 400 MHz NMR spectrometer (Bruker BioSpin SA, Fallanden,
Switzerland) by comparing the signal with a 13C pyruvate reference
sample of a known concentration. The animals blood volumewas calcu-
lated using the relation between total blood volume and body weight
published by Lee and Blaufox [32] and the blood [1-13C]acetate concen-
tration was obtained accordingly.
The in vitro spin-lattice relaxation times of [1-13C]acetylcarnitine
were also measured at 400 MHz in D2O and in freshly collected rat
blood at 37° C using a saturation recovery sequence with proton
decoupling during acquisition.
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implemented in the jMRUI software package [33], was used to ﬁt
the 13C NMR data. The spectra were corrected for the phases and DC
offset. Soft constraints were imposed to peak frequencies (182.55–
182.65 ppm for acetate and 173.85–173.95 ppm for acetylcarnitine)
and line widths (FWHM = 5–30 Hz) and the relative phases were
ﬁxed to zero. The acetylcarnitine peak areas were normalized to the
maximum acetate signal in each experiment to account for varying
polarization levels across experiments. The time courses of quantiﬁed
peak areas were analyzed with the kinetic model described below,
implemented in Matlab (The MathWorks, Natick, MA, USA).
2.1. Kinetic model of acetate metabolism
The uptake of acetate by skeletal muscle tissue as a function of the
arterial concentration is described in [17,18]. Acetate transport across
the cellular membrane occurs by facilitated diffusion, and thus net
transport of acetate between the plasma and the tissue depends on
the concentration gradient. We therefore assumed that the measured
kinetic parameters are independent of processes related to mem-
brane transport. As a result, the variations in conversion rates as a
function of the injected concentration are expected to be directly
correlated to ACS and CAT activity.
In the simplest model of a biochemical reaction, the conversion
from substrate to product in a tissue can be described with a rate con-
stant k that depends on substrate and enzyme concentrations. The as-
sumption is that the enzyme concentration is not inﬂuenced by the
substrate in the short time scale of the experiment, which is about
1 min. Therefore, the 13C (*) label ﬂow between the substrate acetate
(Ace) and the metabolites acetylCoA (A.CoA) and acetylcarnitine
(A.Car) in the skeletal muscle can be described as follows:
d Ace½ 
dt
¼−VACS
Ace½ 
Ace½  ð1Þ
d A:CoA½ 
dt
¼ VACS
Ace½ 
Ace½  −V
f
CAT
A:CoA½ 
A:CoA½  þ V
b
CAT
A:Car½ 
A:Car½  ð2Þ
d A:Car½ 
dt
¼ VfCAT
A:CoA½ 
A:CoA½  − V
b
CAT þ VOUT
  A:Car½ 
A:Car½  ð3Þ
where [Ace], [A.CoA], [A.Car] represent total metabolites concentra-
tions (sum of 13C labeled and unlabeled molecules), [Ace*], [A.CoA*],
[A.Car*] the 13C labeled concentrations, VCATf and VCATb are the forward
and the backward ﬂuxes through CAT, respectively, VACS is the ﬂux
through ACS and VOUT is the ﬂux out of the acetylcarnitine pool (Fig. 1).
Since the physiological plasma acetate concentration is lower than
0.2 mM [5], it can be assumed that the acetate blood pool was fully
labeled following the bolus injection, i.e. [Ace*]/[Ace] ≈ 1. Summing
Eqs. (2) and (3) leads to:
d A:Car½ 
dt
þ d A:CoA
½ 
dt
¼ VACS−VOUT
A:Car½ 
A:Car½  ð4Þ
The acetylCoA pool size is well regulated and is typically more
than 10 times smaller than the acetylcarnitine pool [14], i.e. a small
pool approximation [34,35] can be used, therefore d[AcetylCoA*]/
dt≪ d[Acetylcarnitine*]/dt. The last term in Eq. (4) can be neglected
since, within the short experimental time frame, the acetylcarnitine
pool is only partially labelled and thus a minute amount of 13C label
will reach the mitochondrial acetylCoA pool. This is further supported
by a previous study showing that the contribution of acetate to the
TCA cycle in skeletal muscle was an order of magnitude smallerthan our observed rate of acetylcarnitine formation [36,37]. Condensing
the previous statements, the 13C ﬂow from acetate to acetylcarnitine in
the skeletal muscle can be described by the following two equations:
d Ace½ 
dt
¼−VACS ¼−kACS Ace½  tð Þ ð5Þ
d A:Car½ 
dt
¼ VACS ¼ kACS Ace½  tð Þ ð6Þ
where the kinetic rate constant of ACS is introduced. Based on these
conditions, it was concluded that the observed kinetic rate in these
experiments corresponds to the enzymatic activity of ACS.
The acetate 13C NMR signal measured in skeletal muscle tissue fol-
lowing the injection of hyperpolarized [1-13C]acetate decayed with
time as a consequence of a combination of (a) the loss of spin polar-
ization related to longitudinal relaxation and characterized by an
exponential decay rate R1, (b) the loss of longitudinal magnetization
due to radiofrequency excitations, and (c) the conversion of acetate
into acetylcarnitine characterized by the kinetic rate constant kACS.
The acetylcarnitine signal also decays because of (a) and (b), but (c)
leads to an increase in signal. The time evolution of the carbonyl 13C
longitudinal magnetization of acetate, MA, and acetylcarnitine, MC,
can thus be written as:
dMA
dt
¼−RA MA−MA;eq
h i
−kACSMA ð7Þ
dMC
dt
¼ kACSMA−R1;C MC−MC;eq
h i
ð8Þ
where RA, is the acetate signal decay comprising the carbonyl 13C lon-
gitudinal relaxation rate R1,A as well as the potential [1-13C]acetate
ﬂow of signal in and out of the volume of interest; R1,C is the carbonyl
13C longitudinal relaxation rate of acetylcarnitine: Finally, MA,eq and
MC,eq are the thermal equilibrium magnetizations of the carbonyl
sites of acetate and acetylcarnitine, respectively. The contributions
of MA,eq and MC,eq to the acetate and acetylcarnitine signals can be
neglected since MA ≫ MA,eq and MC ≫ MC,eq when the resonances
are detectable. These Bloch-McConnell differential equations [38]
are identical to the ones derived for the one-compartment non
steady-state metabolic model for one site exchange, which has al-
ready been shown to be applicable to hyperpolarized substrates
[39]. From the initial conditions MC (t = 0) = 0 and MA (t = 0) =
M0 and taking into account the signal losses due to RF excitations,
the hyperpolarized acetate and acetylcarnitine signals, SA(t) and
SC(t), measured at t = nTR, TR being the repetition time, are given by:
SA tð Þ∝MA tð Þ cos θð Þt=TR ¼ M0e −kACS−RAð Þt cos θð Þt=TR ð9Þ
SC tð Þ∝MC tð Þ cos θð Þt=TR ¼ M0 be −kACS−RAð Þt−be−R1;C t
 
cos θð Þt=TR ð10Þ
where b = kACS/(−kACS −RA + R1,C), and θ is the RF pulse ﬂip angle.
The time point of the ﬁrst acetate observation, which also corre-
sponds to the maximum acetate signal, was set to t = 0 prior to
ﬁtting the data with the kinetic model. To relate the signals measured
in the sensitive volume of the surface coil described by Eqs. (9) and
(10) to the cellular concentrations described by Eqs. (4) and (5), it
was assumed that the blood volume in the VOI was small enough to
neglect its contribution to the measured 13C acetate signal. This
was supported by anatomical proton images taken prior to the injec-
tions and previous PET studies which determined a small blood vol-
ume in this area [40]. This assumption is strengthened by a reported
acetate removal of 50% by skeletal muscle in a single passage of
blood [5].
The dependence of the reaction kinetics on the hyperpolarized
substrate concentration was analyzed using the standard Michaelis–
Table 1
Longitudinal relaxation times of [1-13C]acetylcarnitine at a magnetic
ﬁeld strength of 9.4 T in plasma and D2O.
Solvent T1 in seconds
Blood T = 310 K (37 C) 14.9 ± 0.7
D2O T = 295 K 10.3 ± 0.4
D2O T = 305 K 14.3 ± 0.5
D2O T = 310 K 15.5 ± 0.5
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Vmax are the Michaelis constant and the initial reaction rate v0 is the
product of the initial acetate concentration and the kinetic rate con-
stant, i.e., v0,ACS = kACS ⋅ [Ace].
It has been observed that there exists a linear relationship be-
tween the kinetic rate constants obtained using mathematical model-
ling and the ratio of the areas of acetylcarnitine and acetate, a
linearity also observed in studies using hyperpolarized pyruvate
[41]. This linearity in case of hyperpolarized acetate was investigated
by analysing the system of coupled equations deﬁned by Eqs. (9) and
(10) which has only 3 free parameters, namely kACS, RA and R1,C. It is
possible to eliminate RA by integrating the two equations over time
and by taking their relative ratio as described in the Appendix A,
yielding the following relationship:
kACS ¼ R1;C
∫
∞
0
MC tð Þdt
∫
∞
0
MA tð Þdt
≅ R1;C
XN
n¼1
SC n−1ð ÞTRð Þ= cos θ n−1ð Þ
XN
n¼1
SA n−1ð ÞTRð Þ= cos θ n−1ð Þ
ð11Þ
where SC(nTR) and SA(nTR) are the signal intensity obtained at the
nth of the N acquisitions, corrected for the loss of signal due to the
RF pulses for acetylcarnitine and acetate, respectively, by the term
cos θ(n − 1).
3. Results
The incorporation of hyperpolarized 13C label into acetylcarnitine
was detected in all animals (n = 19). The average line width of the
acetate resonance at 182.6 ppm was 21 ± 6 Hz and that of the
acetylcarnitine resonance at 173.9 ppm was 6 ± 1 Hz (Fig. 2). The
ﬁrst acetate signal measured corresponds to the maximum observed
signal which appeared 13.5 ± 2.3 s after the beginning of the injection
and no progressive build-up of the signal was observed. The maximum
acetylcarnitine signalwas detected at a later time, 26.2 ± 3.9 s after theH3C
[1-1
Chemical shift 
180185190195
Fig. 2. Transient 13C NMR spectra of hyperpolarized acetate (182.6 ppm) and its metabolic
the 13C label is catalyzed by the enzymes ACS and CAT. Spectra were acquired every 3 s using
of a 110 mM hyperpolarized acetate was injected. Inset: summation of the spectra as descrbeginning of the injection. The maximal SNR of acetylcarnitine was 10
with zero line broadening and we imposed a minimum SNR threshold
of 3 belowwhich the signalwas not taken into account for data analysis.
In each experiment 1.0 mL of hyperpolarized acetate solution, with a
concentration ranging from 40 to 290 mMwas injected into the femoral
vein. It was estimated that the injected hyperpolarized acetate doses
resulted in a plasma acetate concentration ranging from 1.8 to 15.0 mM
[32]. Using a previously reported relation between plasma and tissue
acetate concentration in rat skeletal muscle [17], it was estimated that
the tissue acetate concentration ranged from 0.12 to 1 mM.
To determine kACS from the system of coupled equations deﬁned
by Eqs. (7) and (8), the longitudinal relaxation time of [1-13C]
acetylcarnitine was set to its in vitro value at 9.4 T, T1,C = 1/R1,C, of
14.9 ± 0.7 s determined in blood at physiological temperature (310 K,
37°C) (Table 1). The T1 of acetylcarnitine in D2O had a value similar to
the T1 in plasma at 310 K. Its T1 decreases with decreasing temperature
(Table 1). The kinetic rate constant kACS was determined by ﬁtting
Eqs. (9) and (10) to the time evolution of the acetate and acetylcarnitine
signal integrals (Fig. 3) yielding kACS and RA. The observed decay of the
acetate signal is mono exponential with a time constant of 16.2 ± 1.4 s.
The values of kACS were determined as a function of the tissue acetate
concentration deduced from the infused acetate dose and the animal
weight (Fig. 4). Yielding the initial reaction rates v0,ACS = kACS ⋅ [Ace]
as a function of the tissue acetate concentration, used to derive the
Michaelis–Menten kinetic parameters (Fig. 4): The conversion of acetate
into acetylcarnitine was characterized by a Michaelis constant KM =13C
O
O-
13C
O
O-
H
N(CH3)3
+
O
O
H3C
3C]Acetate [1-13C]Acetylcarnitine
Tim
e [s
]
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170175
product acetylcarnitine (173.9 ppm) in healthy skeletal muscle in vivo. The transfer of
adiabatic 30° excitation pulses and 1H decoupling during acquisition, a 1.0 mL solution
ibed in Eq. (11) which was used to calculate the kinetic rate constants.
in
fu
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n
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Model Fit
Fig. 3. Time course of the normalized peak integrals of hyperpolarized acetate (●) and
its metabolic product acetylcarnitine (■). The kinetic model described with Eqs. (9)
and (10) was used to ﬁt (- - -) the hyperpolarized time courses to determine the kinetic
rate constant kACS, and the decay rate of acetate RA. The time courses were normalized
to their maximum signal. In the data shown here 1.0 mL of a 110 mM hyperpolarized
acetate solution was injected.
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rate, Vmax, of 0.199 ± 0.031 μmol/g/min. The summation approach esti-
mated a KM = 0.32 ± 0.12 mMand Vmax, of 0.190 ± 0.029 μmol/g/min.
To further demonstrate that the kinetic rate constant is uniquely
determined when the relaxation rate of acetylcarnitine R1,C is ﬁxed,
kACS was calculated for all experiments using Eq. (11) and plotted
against the kinetic rate constants obtained from the ﬁtting procedure
(Fig. 5). The residual differences are most likely due to the ﬁtting
errors inherent to the limited signal-to-noise ratio.0.2 0.4 0.6 0.8 1 1.2 1.40
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Fig. 4. The relation between the initial reaction rates v0,ACS (top row) and kinetic rate con
hyperpolarized experiment provided one kinetic rate constant kACS (■) and associated stan
summation approach (right column). The initial reaction rate was obtained by multiplying
Michaelis–Menten parameter ﬁts are represented by the dashed line. Using model ﬁtting a
the summation approach a KM of 0.32 ± 0.12 mM and Vmax of 0.190 ± 0.029 μmol/g/min w4. Discussion
The present study demonstrates that kinetic rates for the conversion
of acetate to acetylcarnitine can be derived from in vivo hyperpolarized
magnetic resonance experiments and that these rates are in very good
agreement with the ones determined in in vitro experiments. The plas-
ma acetate concentrations used in the current study (1.8–15.1 mM)
have been previously shown to linearly scale with the uptake of acetate
in skeletal muscle tissue and thus with the cellular acetate concentra-
tion [17,18]. This implies that the kinetic parameters extracted from
the in vivo real-time measurements presented herein are independent
of processes related to membrane transport since acetate uptake by
resting skeletal muscle is proportional to the arterial concentration.
Therefore, the variations in conversion rates as a function of the injected
concentration are thus directly correlated to the biochemical transfor-
mations regulated by ACS and CAT in the cytosol. CAT also resides in
the mitochondria where it converts acetylcarnitine back into acetylCoA
followed by entry into the TCA cycle and 13C MRS cannot distinguish
between the two compartments. However, since compared to other
substrates there is a relatively small (~3%) contribution of acetate to
mitochondrial acetylCoA in the skeletal muscle [36,37], and in addition
the cytosolic acetylcarnitine pool is only partially labelled during the
short duration of the experiments, it is expected that the [1-13C]
acetylcarnitine signal almost exclusively originates from the cytosol.
The tissue concentrations used in the present study (0.12–
1.00 mM) were approximately an order of magnitude lower than
those used to maximally acetylate free carnitine and CoA in canine
skeletal muscle [15] and human skeletal muscle at rest [42–44]. This in-
dicates that the observed acetylcarnitine formation was not hinderedVmax= 0.190+/- 0.029 µmol/g/min
KM = 0.32 +/- 0.12 mM
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Fig. 5. The linear relationship between the kinetic rate constants kACS obtained with mathematical modeling of the metabolite time courses and the ratio of the sum of RF corrected
peak integrals of acetylcarnitine (C(t)) and acetate (A(t)) was used to calculate an integral derived kinetic rate constant (Eq. (11)). The integral derived kinetic rate constant equals
the integral ratio times the longitudinal relaxation rate of acetylcarnitine R1,C. The relationship between the kinetic rate constants derived from the metabolic model versus the
kinetic rate constants derived using the relative areas of hyperpolarized acetylcarnitine and acetate are shown below.
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constants range from ~2 to 6 ms−1, showing that substrate concentra-
tion is an important parameter to take into account while designing
a study using hyperpolarized acetate as a metabolic tracer. It was also
observed that this conversion is not saturated even at a tissue concen-
tration of acetate as high as 1 mM.
Our analysis based on the assumption that, during the experimen-
tal time frame, the acetate pool is fully labeled and the time variation
of the acetylCoA pool labeling is much smaller than the one of
acetylcarnitine led to the conclusion that the kinetic rates corre-
sponds to the conversion rate associated with the enzyme acetylCoA
synthetase. This is further supported by the fact that the transforma-
tion catalyzed by ACS is the rate-limiting step in the transformation
of acetate into acetylcarnitine [4]. It needs to be mentioned that the
reaction through ACS is irreversible and there is no direct exchange
between acetate and acetylcarnitine. Previous reported ACS activity
suggested an in vitro KM of 0.2 mM for acetate [20]. Following acetate
infusions in rat and sheep, theMichaelis constant for acetate in the ACS
reaction was between 0.28 and 0.39 mM, based on tissue extracts, with
no marked differences between species, tissue or the intracellular loca-
tion of the enzyme activity [5]. These values ofKM are in agreementwith
our observed Michaelis constant.
Based on the linear relationship between the ratio of signal integrals
and the kinetic rate constants, two approacheswere used to extract kACS
from the data: One was based on time evolution ﬁtting of the signal
integrals (Eqs. (9) and (10)) and the other on the relative ratio of the
sum of both substrate and product (Eq. (11)). Note that, while the
ﬁrst requires the use of mathematical modeling, the summation ap-
proach is simpler but less accurate because each individual spectrum
has to be divided by a factor of cos θ(n − 1) according to Eq. (11),
where n is the acquisition number, leading to noise error propagation,
whereas the ﬁt of the time series takes into account the RF decay and
only relies on raw data. Other approaches based on mathematical
modeling of themetabolic time coursewere previously proposed to de-
termine the conversion rates fromhyperpolarized 13C-labeled pyruvate
to its downstream metabolites [39,45,46].
Acetylcarnitine 13C labeling in the heart has been previously
reported following the infusion of hyperpolarized [2-13C]pyruvate[26,27], but unlike pyruvate, acetate is independent of PDH ﬂux.
The utilization of acetate by the TCA cycle is strictly aerobic and
depending on the delivery of both acetate and oxygen [5], the conver-
sion rate constants are expected to be strongly dependent on the
oxygenation of the tissue under investigation and TCA cycle activity:
Itwas previously shown that intensemuscle activity lead to an accumu-
lation of acetylcarnitine [11], and that a decreased exchange between
acetylcarnitine and acetate was a relevant marker for ischemia [25].
The possibility to monitor the acetylcarnitine kinetics in vivo in a mea-
surement window of 1 min in a non-invasive manner and the extrac-
tion of speciﬁc enzymatic activities can be expected to be a valuable
tool for differentiating between healthy and pathological metabolism,
in particular since the conversion rate regulated by ACS is implicated
in disorders like diabetes [47] or cancer [48].
5. Conclusions
The conversion rates fromhyperpolarized acetate into acetylcarnitine
can be quantiﬁed in vivo, and although separated by two enzymatic reac-
tions, these rates deﬁne uniquely the activity of acetylCoA synthetase.
It was further shown that these rates can be obtained using either ﬁtting
of time courses, or an analysis based on time course integration, both
approaches yielded similar enzymatic activity. This study showed the
feasibility of measuring the activity of acetylCoA synthetase in vivo.
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Appendix A
Derivation of Eqs. (11) from (9) and (10)
The transient magnetization of hyperpolarized acetate and its
metabolic product acetylcarnitine can be described as follows:
MA tð Þ ¼ M0e −kACS−RAð Þt
MC tð Þ ¼ M0 be −kACS−RAð Þt−be−R1;C t
 
With b = kACS/(−kACS − RA + R1,C). Integration of both equations
from t = 0 to inﬁnity results in the following
∫
∞
0
MA tð Þdt ¼ M0∫
∞
0
e −kACS−RAð Þtdt ¼ M0
e −kACS−RAð Þt
−kACS−RAð Þ

0
∞
¼− M0
kACS þ RA
∫
∞
0
MC tð Þdt ¼ bM0∫
∞
0
e −kACS−RAð Þtdt−bM0∫
∞
0
e−R1;C tdt ¼− M0b
kACS þ RA
þM0b
R1;C
∫
∞
0
MC tð Þdt
∫
∞
0
MA tð Þdt
¼
− M0b
kACS þ RA
þM0b
R1;C
− M0
kACS þ RA
¼ b 1− kACS
R1;C
− RA
R1;C
 !
¼
∫
∞
0
MC tð Þdt
∫
∞
0
MA tð Þdt
¼ kACS−kACS−RA þ R1;C
 !
−kACS−RA þ R1;C
R1;C
 !
¼ kACS
R1;C
kACS ¼ R1;C
∫
∞
0
MC tð Þdt
∫
∞
0
MA tð Þdt
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SC n−1ð ÞTRð Þ= cos θ n−1ð Þ
XN
n¼1
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